Menu Search
Equities

Biodexa Pharmaceuticals PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5MP:FRA

Biodexa Pharmaceuticals PLC

Actions
  • Price (EUR)56.50
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta1.0268
Data delayed at least 15 minutes, as of Oct 03 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.40m
  • Incorporated2014
  • Employees13.00
  • Location
    Biodexa Pharmaceuticals PLC1 Caspian Point, Caspian WayABINGDON CF10 4DQUnited KingdomGBR
  • Phone+44 123 584 1575
  • Websitehttps://www.biodexapharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.